Halozyme Therapeutics | HALO - Ebitda


Halozyme Therapeutics reported $219.57M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
Amgen USD 5.14B 775M Dec/2025
Baxter International USD -447M 873M Dec/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Cytokinetics USD -169.32M 19.48M Mar/2026
DBV Technologies USD -33.48M 5.55M Sep/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
Intrexon USD -24.7M 2.92M Jun/2024
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
MannKind USD -3.05M 20.97M Dec/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Nektar Therapeutics USD -31.81M 70K Sep/2023
Pfizer USD 5.99B 5.23B Mar/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
United Therapeutics USD 379.5M 83.4M Dec/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024